ArticleFrontiers in oncology2025
Deep learning-assisted diagnosis of liver tumors using non-contrast magnetic resonance imaging: a multicenter study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Artificial Intelligence in Hepatocellular Carcinoma: Current Applications, Clinical Performance, and Barriers to Implementation.Journal of clinical medicine · 2026Review
- Radiomics for Detection and Differentiation of Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis.Cancers · 2026Review
- Artificial Intelligence in the Diagnosis and Prognostic Stratification of Hepatocellular Carcinoma: Current Evidence, Clinical Applications, and Future Perspectives.Biomedicines · 2026Review
- Application of artificial intelligence in hepatology.Frontiers in digital health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Non-contrast MRI(NC-MRI) is an attractive option for liver tumors screening and follow-up. This study aims to develop and validate a deep convolutional neural network for the classification of liver lesions using non-contrast MRI. Methods: A total of 50418 enhanced MRI images from 1959 liver tumor patients across three centers were included. Inception-ResNet V2 was used to generate four models through transfer-learning for three-way lesion classification, which processed T2-weighted, diffusion-weighted (DWI) and multiphasic T1-weighted images. The models were then validated using one independent internal and two external datasets with 5172, 2916, and 1338 images, respectively. The efficacy of non-contrast models (T2,T2+DWI) in differentiating between benign and malignant liver lesions at the patient level was also evaluated and compared with radiologists. The performance of models was evaluated using the area under the receiver operating characteristic curve (AUC),sensitivity and specificity. Results: Similar to multi-sequence and enhanced image-based models, the non-contrast models showed comparable accuracy in classifying liver lesions as benign, primary malignant or metastatic. In the independent internal cohort, the T2+DWI model achieved AUC of 0.91(95% CI,0.888-0.932), 0.873(0.848-0.899), and 0.876(0.840-0.911) for three tumour categories, respectively. The sensitivities for distinguishing malignant tumors in three validation sets were 98.1%, 89.7%, and 87.5%%, with specificities over 70% in all three sets. Conclusions: Our deep-learning-based model yielded good applicability in classifying liver lesions in non-contrast MRI. It provides a potential alternative for screening liver tumors with the advantage of reducing costs, scanning time and contrast-agents risks. It is more suitable for benign tumours follow-up, surveillance of HCC and liver metastasis that need periodic repetitive examinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.